Hemenway Trust Co LLC reduced its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 10.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 35,580 shares of the life sciences company’s stock after selling 4,129 shares during the quarter. Illumina accounts for approximately 2.2% of Hemenway Trust Co LLC’s investment portfolio, making the stock its 19th biggest holding. Hemenway Trust Co LLC’s holdings in Illumina were worth $13,060,000 at the end of the most recent quarter.
Other hedge funds have also recently bought and sold shares of the company. Kaizen Advisory LLC boosted its stake in shares of Illumina by 161.0% during the 2nd quarter. Kaizen Advisory LLC now owns 368 shares of the life sciences company’s stock worth $103,000 after acquiring an additional 227 shares in the last quarter. Sun Life Financial INC boosted its stake in shares of Illumina by 152.5% during the 2nd quarter. Sun Life Financial INC now owns 399 shares of the life sciences company’s stock worth $111,000 after acquiring an additional 241 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. boosted its stake in shares of Illumina by 3,192.3% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 428 shares of the life sciences company’s stock worth $120,000 after acquiring an additional 415 shares in the last quarter. Hall Laurie J Trustee boosted its stake in shares of Illumina by 189.5% during the 2nd quarter. Hall Laurie J Trustee now owns 550 shares of the life sciences company’s stock worth $154,000 after acquiring an additional 360 shares in the last quarter. Finally, Fulton Bank N.A. purchased a new position in Illumina in the 3rd quarter valued at about $202,000. 89.90% of the stock is currently owned by institutional investors and hedge funds.
A number of brokerages recently weighed in on ILMN. Zacks Investment Research lowered shares of Illumina from a “buy” rating to a “hold” rating in a research note on Wednesday, October 24th. Barclays raised their price target on shares of Illumina from $350.00 to $370.00 and gave the company an “overweight” rating in a research note on Wednesday, October 24th. BidaskClub lowered shares of Illumina from a “buy” rating to a “hold” rating in a research note on Tuesday, October 16th. Deutsche Bank raised their price target on shares of Illumina to $350.00 and gave the company a “buy” rating in a research note on Friday, October 12th. Finally, ValuEngine lowered shares of Illumina from a “strong-buy” rating to a “buy” rating in a research note on Thursday, October 11th. Six research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $330.94.
ILMN opened at $322.73 on Wednesday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 2.24 and a current ratio of 2.46. Illumina, Inc. has a 1-year low of $203.83 and a 1-year high of $372.61. The company has a market capitalization of $48.23 billion, a price-to-earnings ratio of 80.68, a price-to-earnings-growth ratio of 2.43 and a beta of 1.07.
Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, October 23rd. The life sciences company reported $1.52 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.26 by $0.26. Illumina had a net margin of 21.09% and a return on equity of 27.10%. The business had revenue of $853.00 million for the quarter, compared to analyst estimates of $825.65 million. During the same period last year, the company posted $1.11 EPS. The business’s revenue was up 19.5% on a year-over-year basis. Sell-side analysts forecast that Illumina, Inc. will post 5.75 EPS for the current fiscal year.
In other Illumina news, SVP Oene Mark Van sold 1,091 shares of the firm’s stock in a transaction that occurred on Tuesday, September 4th. The shares were sold at an average price of $354.18, for a total value of $386,410.38. Following the transaction, the senior vice president now directly owns 11,126 shares of the company’s stock, valued at approximately $3,940,606.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Francis A. Desouza sold 2,100 shares of the firm’s stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $369.61, for a total transaction of $776,181.00. The disclosure for this sale can be found here. Insiders sold a total of 55,629 shares of company stock worth $18,631,589 over the last three months. Corporate insiders own 0.54% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Enterprise Leader and is owned by of Enterprise Leader. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://theenterpriseleader.com/2018/11/07/hemenway-trust-co-llc-sells-4129-shares-of-illumina-inc-ilmn.html.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Further Reading: Trading Penny Stocks
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.